Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
4 search results for:

Mavrilimumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 06-06-2021 | EULAR 2021 | Conference coverage | Article

    Mavrilimumab shows potential for severe COVID-19

    Inhibition of GM-CSF with mavrilimumab may represent a promising treatment option for patients with severe COVID-19 pneumonia and systemic hyperinflammation, suggest phase 2 study results.

    Author:
    Claire Barnard
    Published in:
    EULAR 2021 Virtual Congress; 2–5 June
  2. 10-11-2020 | ACR 2020 | Conference coverage | Article

    Reduced flare risk with mavrilimumab in giant cell arteritis

    Mavrilimumab is effective for reducing the risk for flare and maintaining sustained remission in patients with giant cell arteritis, phase 2 study findings show.

    Author:
    Lucy Piper
    Published in:
    ACR Convergence virtual meeting; 5–9 November 2020
  3. 06-02-2018 | Rheumatoid arthritis | News | Article

    Mavrilimumab offers sustained efficacy in RA without increased TEAE risk

    Mavrilimumab efficacy is sustained over the long-term treatment of rheumatoid arthritis without an increase in the incidence of treatment-emergent adverse events, long-term results from two phase IIb trials and an extension study suggest.

    Published in:
    Arthritis Rheumatol 2018; Advance online publication
  4. 26-04-2019 | Rheumatoid arthritis | News | Article

    Namilumab shows promise in phase II trial

    . © 2019 Springer Healthcare part of the Springer Nature group Arthritis Res Ther 2019; 21 : 101 See also: Mavrilimumab offers sustained efficacy in RA without increased TEAE risk

    Published in:
    Arthritis Res Ther 2019; 21 : 101
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.